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ABSTRACT
Objectives: The aim of this study was to investigate
the surgical revision rate in patients with chronic
rhinosinusitis (CRS) in the UK CRS Epidemiology
Study (CRES). Previous evidence from National
Sinonasal Audit showed that 1459 patients with CRS
demonstrated a surgical revision rate 19.1% at 5 years,
with highest rates seen in those with polyps (20.6%).
Setting: Thirty secondary care centres around the UK.
Participants: A total of 221 controls and 1249
patients with CRS were recruited to the study including
those with polyps (CRSwNPs), without polyps
(CRSsNPs) and with allergic fungal rhinosinusitis
(AFRS).
Interventions: Self-administered questionnaire.
Primary outcome measure: The need for previous
sinonasal surgery.
Results: A total of 651 patients with CRSwNPs, 553
with CRSsNPs and 45 with AFRS were included.
A total of 396 (57%) patients with CRSwNPs/AFRS
reported having undergone previous endoscopic nasal
polypectomy (ENP), of which 182 of the 396 (46%)
reported having received more than one operation. The
mean number of previous surgeries per patient in the
revision group was 3.3 (range 2–30) and a mean
duration of time of 10 years since the last procedure.
The average length of time since their first operation
up to inclusion in the study was 15.5 years (range
0–74). Only 27.9% of all patients reporting a prior ENP
had received concurrent endoscopic sinus surgery
(ESS; n=102). For comparison, surgical rates in
patients with CRSsNPs were significantly lower; 13%
of cases specifically reported ESS, and of those only
30% reported multiple procedures (χ2 p<0.001).
Conclusions: This study demonstrated that there is a
high burden of both primary and revision surgery in
patients with CRS, worst in those with AFRS and least
in those with CRSsNPs. The burden of revision surgery
appears unchanged in the decade since the Sinonasal
Audit.
INTRODUCTION
Rhinosinusitis is one of the most common
chronic adult health problems in the Western
world with a recent European study estimat-
ing the prevalence of chronic rhinosinusitis
(CRS) at 11%,1 although in studies with
physician-led diagnosis of CRS, a prevalence
of 6–7% has been observed.2 3 Sinonasal
surgery for patients with CRS is commonly
performed by otorhinolaryngologists around
the UK. Hospital Episode Statistics (HES)
data for 2012–2013 suggest that approxi-
mately 40 000 nose or sinus operations are
performed each year in England and Wales;
this is in addition to an estimated 75 000 out-
patient consultations.3 Patients selected for
surgical intervention should have failed to
improve symptomatically on medical treat-
ment, but there is a greater than ﬁvefold vari-
ation in intervention rates across the UK.4
This variation may reﬂect a number of factors
including both underutilisation and overutili-
sation of surgery, a lack of guidelines and a
lack of evidence in well-constructed rando-
mised controlled trials (RCTs) to support
Strengths and limitations of this study
▪ Large cohort of patients from secondary and ter-
tiary care centres around the UK.
▪ Chronic rhinosinusitis is a common disease and
sinonasal surgery is frequently undertaken.
▪ The data are derived from self-reported question-
naire responses by patients.
▪ There is selection bias as only symptomatic
patients returning to secondary care are included
in the study.
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surgery;5 a 2005 Health Technology Assessment commis-
sioned systematic review of sinus surgery identiﬁed the
need for good quality studies comparing surgery with
medical treatment for CRS with nasal polyps
(CRSwNPs).6 Furthermore, the duration of uncontrolled
symptoms before surgery varies considerably between 1
and 10 years.7 This uncertainty regarding the role of
surgery is highlighted by its inclusion in the National
Institute for Health and Care Excellence (NICE)
Database of Uncertainties about the effects of treatment
(DUETs).8 Although level 1 evidence is lacking, recent
studies evaluating the symptomatic and economic bene-
ﬁts of surgical intervention in CRS outside of the UK
National Health Service (NHS) setting favour surgical
intervention over ongoing medical therapy.9–12
In 2000–2001, a total of 3128 consecutive patients
undergoing surgery for CRS at 87 NHS hospitals were
enrolled as part of the UK Sinonasal Audit coordinated
through the Clinical Effectiveness Unit at the Royal
College of Surgeons of England.13 All of the 156 NHS
Trusts in England and Wales performing sinonasal
surgery were invited to take part in the Audit; those who
failed to participate largely cited ﬁnancial constraints as
the reason for refusal. All patients aged 16 years or more
and who had elected to undergo surgical procedures to
treat nasal polyposis and/or CRS were eligible for inclu-
sion. Although this study concluded that sinonasal
surgery is generally safe and effective and that patient
selection for surgery could be improved, the subsequent
long-term follow-up of audit patients also demonstrated
the limitations of sinus surgery in current practice.14
From the 1459 patients who responded to 5-year
follow-up, revision surgery rates increased at each time
point such that 19.1% had undergone further sinonasal
surgery during the 5 years since their original operation.
In CRSwNPs, 20.6% had undergone revision compared
with 15.5% of patients with CRS without nasal polyposis
(CRSsNPs). Looking at cases where a simple polypect-
omy was performed, 21.2% had undergone revision
surgery compared with 20.0% of patients who had also
received additional sinus surgery with an adjusted OR of
0.66 (p=0.04) for the risk of the latter group needing
further surgery.
Given these interventions occurred 13–14 years ago
during which time there have been advances in instru-
mentation and visualisation for sinonasal surgery, the
CRS Epidemiology Study (CRES) provided an opportun-
ity to revisit this scenario using recent data. CRES pro-
spectively collected a national cohort of self-reported
patient data in the UK (excluding Northern Ireland).
The overarching aim of the CRES was to identify any
difference in socioeconomic variables between patients
with CRS and healthy controls using a study-speciﬁc
questionnaire which included demographic and socio-
economic questions as well as disease-speciﬁc and
generic quality of life tools. The study included a qualita-
tive arm exploring patient experiences in detail. The
CRES questionnaire also allowed collection of
information about previous surgical interventions, allow-
ing us to investigate surgical revisions and allow compari-
son of management between subgroups of CRS. Revision
surgery is herein deﬁned as any further surgical interven-
tion for CRS (ie, repeated nasal polypectomy or repeated
endoscopic sinus surgery (ESS).
MATERIALS AND METHODS
The CRES was sponsored by the University of East
Anglia (UEA). Any patients presenting to secondary
care outpatient clinics and diagnosed by an otorhino-
laryngologist with CRS as deﬁned by the criteria laid out
in the European Position Paper on Rhinosinusitis and
Nasal Polyps (EPOS) were invited to participate in the
study regardless of symptom or disease severity or dur-
ation and regardless of any prior interventions. The
study initially started recruitment in the East Anglia
region of the UK but following elevation to the National
Institute of Health Research Clinical Research Network
Portfolio, a total of 30 sites from around the UK (includ-
ing the devolved nations of Wales and Scotland) joined
the study which ran between 2007 and 2013. The study-
speciﬁc questionnaire was anonymous, and therefore no
consent was taken but implied through their participa-
tion. Patients were classiﬁed by subgroup of CRS
(CRSsNPs, CRSwNPs or allergic fungal rhinosinusitis
(AFRS) by a clinician prior to completion of the ques-
tionnaire using the EPOS deﬁnitions for with or without
polyps (using endoscopic and/or radiological conﬁrm-
ation) and the Bent and Kuhn criteria for AFRS.
Questionnaires were either completed before leaving the
clinic or taken home and returned by post in freepost
envelopes. The returned questionnaires were then
scanned into a database electronically but checked by
two members of the research team for accurate correl-
ation with the paper questionnaire and for missing data.
The study questionnaire includes study-speciﬁc questions
relating to socioeconomic, environmental and medical
comorbid variables as well as the validated Short Form
36 (SF-36)15 quality of life measure and the Sino-Nasal
Outcome (SNOT-22)16 questionnaire. A pilot study
demonstrated incomplete responses to the question
“Have you ever had any nasal surgery?” due to some par-
ticipants excluding sinus surgery from their responses.
The questionnaire therefore stated “Have you had any
previous surgery—yes/no?; If yes, please specify what
and when”, followed by a free ﬁeld text box. This cap-
tured all forms of sinonasal surgery; the frequency of
surgery and any other type of surgery undergone by par-
ticipants and the dates provided by participants varied
from exact dates to just the year of surgery. The self-
reported questionnaire was the only means of data
capture in relation to surgery. These surgery-speciﬁc
data were collated and subcategorised where data were
available (see ﬂow chart). If participants did not com-
plete the surgery text box, they were assumed not to
have undergone any previous surgery and as such there
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were no missing data in this respect. The duration of
time since the most recent surgical intervention pro-
vided and completion of the questionnaire is described
as ‘recurrence time’. The study was powered based on
the ability to detect differences in quality of life between
cases and controls since this was the primary purpose of
the study. The percentage of respondents with previous
surgeries were compared across the three subgroups
(CRSsNPs, CRSwNPs and AFRS) using a χ2 test. The
mean SNOT-22, surgical impact and time to recurrence
were compared between the three subgroups using ana-
lysis of variance (ANOVA).
RESULTS
A total of 1470 completed questionnaires were returned
by participants including 1249 patients with CRS, reﬂect-
ing a response rate across all sites of 66%. The age range
of all participants was 18–102 years, mean 52.6 years, with
709 men and 606 women (155 did not identify their
gender; see ﬁgure 1 ﬂow chart). Patients with CRS diag-
nosed by their ENT surgeon included 651 with CRSwNPs,
553 with CRSsNPs and 45 with AFRS. From the total of
1249 CRS participants, 556 (45%) had undergone some
form of sinonasal surgery (deﬁned as one or more of
polypectomy, ESS, septoplasty, turbinate surgery, rhino-
plasty) including 325 (26%) who had received at least
one nasal polypectomy and 169 (14%) who had under-
gone at least one instance of ESS (ﬁgure 2).
Combining data for the subgroups of CRSwNPs and
AFRS (n=696), 396 (57% of those with CRSwNPs or
AFRS) reported previous ‘sinonasal surgery’ of which
99/696 (14%) reported having undergone ESS and
315/696 (45%) nasal polypectomy. Looking speciﬁcally
at patients with CRSwNPs who underwent a polypectomy
(n=281), only 30% (n=85) reported concurrent ESS. In
cases of CRSsNPs (n=553), only 160 (29%) patients
reported sinonasal surgery in whom 70 (13%) speciﬁc-
ally reported ESS (see table 1 for summary data). A χ2
test showed that the difference between the subgroups
was highly signiﬁcant (p<0.001). Other nasal procedures
speciﬁcally reported included septoplasty and turbinate
surgery.
Considering multiple procedures, 157 of 315 patients
with CRS who reported having undergone a nasal poly-
pectomy previously (50%) had received more than one
operation with a mean number of 3.3 polypectomies
(range 2–30; ﬁgure 3). In contrast, in the CRSsNPs sub-
group, 21 of 160 (13%) participants reported repeated
sinonasal surgery. A χ2 test showed that the difference
between the subgroups was again highly signiﬁcant
(p<0.001).
Looking at the timeline for participants who under-
went sinonasal surgery, 318 reported dates for surgery,
with the average duration from ﬁrst reported surgery to
inclusion in the study being 15.5 years (range 0–74;
table 2 and ﬁgure 4). Although patients may have
become asymptomatic for periods between interven-
tions, these data give a perspective on the chronicity of
the disease (from ﬁrst intervention), especially as many
patients will have been symptomatic for months to years
before the ﬁrst referral to secondary care. The duration
of time since the most recent surgical intervention to
completion of questionnaire (most current consultation)
Figure 1 Flow chart for inclusion of surgical data from CRES (CRS, chronic rhinosinusitis; CRES, CRS Epidemiology Study).
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is called ‘recurrence time’ and ranged from 0 to
70 years with a mean of 10 years for all CRS but notably
a mean of 3.68 in patients with AFRS, being signiﬁcantly
shorter than CRSwNPs (p=0.005; table 3 and ﬁgure 5).
The median interval for revision surgery in patients with
AFRS was 2 years.
Asthma and aspirin-exacerbated respiratory disease
were signiﬁcantly more likely to be present in patients
who had had multiple surgeries (60% asthma, 35%
AERD) than those who had not (43% and 11%; χ2
p>0.001). Finally a comparison in SNOT-22 scores
between patients with CRSwNPs/AFRS who have had
multiple endoscopic nasal polypectomies (ENPs) and
those who reported no surgery shows a signiﬁcantly
higher mean score in the multiple surgery group (45.6
vs 37.9; p=0.001); a mean SNOT-22 score of 42.1 in
those patients reporting only one ENP was not signiﬁ-
cantly different. ANOVA for SNOT-22 scores regardless
of surgery showed only a signiﬁcant difference between
CRSwNPs and AFRS subgroups (p=0.043). A more
detailed analysis of factors inﬂuencing disease in CRS
will be reported elsewhere.
Figure 2 Frequency of
sinonasal surgery (AFRS, allergic
fungal rhinosinusitis; CRSsNPs,
chronic rhinosinusitis without
nasal polyps; CRSwNPs, chronic
rhinosinusitis with nasal polyps).
Table 1 Summary data (percentages expressed with total in each subgroup as the denominator)
Variable CRSsNPs CRSwNPs AFRS
CRSwNPs and
AFRS combined
Total number of respondents 553 651 45 696
Male, % 41.4 59.8 55.6 –
Mean age 51.8 56 56.1 –
Previous sinonasal surgery 160 (29%) 359 (55%) 37 (82%) 396 (57%)
Previous ENP 10 (2%) 281 (43%) 34 (76%) 315 (45%)
Previous ESS 70 (13%) 85 (13%) 14 (31%) 99 (14%)
Multiple ESS/ENPs 21 (4%) 131 (20%) 26 (58%) 157 (23%)
Mean ENPs – 2.98 3.12 3.01
Mean SNOT-22 score 44.2 43.1 50.1 –
AFRS, allergic fungal rhinosinusitis; CRSsNPs, chronic rhinosinusitis without nasal polyps; CRSwNPs, chronic rhinosinusitis with nasal
polyps; ENP, endoscopic nasal polypectomy; ESS, endoscopic sinus surgery; SNOT-22, Sino-Nasal Outcome.
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DISCUSSION
The data from the CRES depict a story of the burden of
CRS on the NHS with more than half the cases of
CRSwNPs and AFRS reporting previous surgical inter-
vention and nearly half of those with surgical interven-
tion having had more than one procedure. As these
patients were all at varying points in their journey as suf-
ferers of CRS with some having undergone prior inter-
vention in secondary care and others having previously
received only treatment in primary care (having been
recruited at their ﬁrst appointment in secondary care),
we believe the study population includes a wide range of
CRS sufferers, rather than a speciﬁc surgical cohort, and
the SNOT-22 scores reﬂect a range of severity (0–108)
with overall recruitment across all sites being 66% of
those approached for participation.
Limitations of this study data are that they are self-
reported and patients may not accurately recollect the
details of the procedures. There are no data on non-
responders, given the anonymous nature of the study.
Although there were large numbers of non-surgical
cases reported, there is a potential bias towards those
who had received surgical intervention, given the sec-
ondary care setting of the study and that GPs will often
refer patients when they believe medical treatment has
been exhausted. The study did however aim to recruit
all patients seen with CRS, including those only receiv-
ing medical intervention in the outpatient setting.
There is a selection bias in terms of location as only
patients undergoing treatment in ENT departments
were recruited—there may be many patients who have
had successful previous surgery who will be missed as
they are no longer requiring active care or are only
receiving treatment in primary care; capturing this wider
picture of patient journeys across primary and secondary
care may become more of a reality now, with the advent
of health informatics such as the Clinical Practice
Research Datalink (CPRD).17 The study was designed to
review patients with CRS at one given point of time for
each participant, and since reported duration of disease
for each participant varied considerably, it is difﬁcult to
accurately establish the size of the population at all time
frames. Strengths of the study include the spread of data
from across the UK, representing both smaller district
general hospitals and larger tertiary centres as well as
different urban and rural populations.
Comparison with the UK Audit data
The UK Sinonasal Audit found that 46.1% of patients
had undergone sinonasal surgery before participating in
the study, with 52.5% of those with CRSwNPs reporting
previous surgery, compared with 35.0% of CRSsNPs. In
comparison, CRES has found slightly lower rates of
patients with CRS overall reporting previous surgery,
43% of all patients with CRS, but 57% of CRSwNPs and
29% of CRSsNPs. This may reﬂect the point of recruit-
ment being different; Audit patients were recruited at
the time of surgery, while CRES patients were recruited
at the time of outpatient treatment, recruiting just those
eligible for surgery in the Audit is likely to recruit more
severely affected patients than a cohort being treated in
outpatients; however, the mean SNOT-22 scores were
very similar with a mean preoperative score of 42 in the
Audit and a mean of 43.9 in CRES. The median time to
previous operation in the UK Audit and in CRES was
6 years.
Our study found the highest rate of revision surgery to
be among those with CRSwNPs and AFRS, with rates of
previous surgery almost twice that of those without nasal
polyps which is supported by the UK Sinonasal Audit.
There is a growing acceptance that patients with and
without polyps have distinct differences. This is reﬂected
in the current iteration of EPOS, with different treat-
ment algorithms for the two main phenotypes. The role
of surgery in patients with CRSwNPs is likely to be no
Figure 3 Frequency of multiple ENPs being performed in
patients who have previously undergone surgery. AFRS,
allergic fungal rhinosinusitis; CRSwNPs, chronic rhinosinusitis
with nasal polyps; ENP, endoscopic nasal polypectomy.
Table 2 Surgical impact data
Diagnosis
Number of patients
with available data Mean Median
Standard
deviation Range
AFRS 23 10.7 9 7.9 33
CRSwNPs 212 16.2 13 14.0 74
CRSsNPs 83 15.0 11 13.3 48
AFRS, allergic fungal rhinosinusitis; CRSsNPs, chronic rhinosinusitis without nasal polyps; CRSwNPs, chronic rhinosinusitis with nasal
polyps.
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more than achieving topical access to intranasal therap-
ies, and it may not change the underlying pathophysio-
logical process. The need for recurrent treatment is
therefore not unexpected. A recent study18 found that
ostiomeatal obstruction is not a feature of CRSwNPs,
and surgery, which primarily alleviates obstruction, is
unlikely to be curative. In contrast, ostiomeatal obstruc-
tion is much more common in CRSsNPs, and therefore
ESS which addresses this may well achieve long-term
beneﬁts. This contrasts to one previous study19 which
found no difference in recurrence rates between those
with and without polyps. It is not clear at this time
whether the high revision rates seen in CRSwNPs simply
reﬂect the chronic nature of the condition and the lim-
itations of current medical management, or whether
there are operative variables that may be improved in
order to reduce the ongoing burden of revision surgery.
CRSwNPs patients are likely to reﬂect a diverse group,
with differing individual patient factors (endotypes) that
are yet to be fully understood and characterised. The
presence of asthma appears to represent a higher risk
factor for recurrence.20 Similarly, a previous study has
also shown higher rates for repeat surgery among those
with aspirin-exacerbated respiratory disease21 (risk-OR of
2.7). One additional patient factor which may inﬂuence
rates and times to revision surgery is smoking status, Wu
et al showed that smokers had a shorter time to revision
surgery,22 but with only 11 smokers in those with mul-
tiple ENPs in CRES, this trend was difﬁcult to quantify.
A crucial factor in the success or failure of surgical
intervention will be patient compliance with ongoing
medical management postoperatively. Although informa-
tion on medical treatment was recorded, this cannot be
speciﬁcally aligned with the postoperative period in
these patients and is not considered further in this ana-
lysis. Anecdotal evidence from the qualitative arm of the
CRES suggests that compliance with topical treatments is
a problem and that patient education at the outset of
treatment is crucial with a need for regular reinforce-
ment.23 This may currently be counteracted by differing
advice from primary and secondary care practitioners
and emphasises the need for greater awareness of guide-
lines, but there is also a need for further clinical trials in
terms of medical treatment to underpin this.
We acknowledge that recurrence of disease reﬂecting
its chronic nature is a more common occurrence than
revision due to ‘failed’ surgery in its truest sense. While
we accept the term ‘revision’ suggests failure of the
primary surgery and that recent evidence shows early
postoperative beneﬁts from sinus surgery,24 for the
reasons cited above (extent of surgery and grade of
surgeon) we feel consideration needs to be given to the
longer term perspective on surgical management in
CRS. As such there is a need for trials that address these
factors, so that we can better understand whether these
repeated surgical interventions reﬂect a disease-speciﬁc
burden or are a product of current surgical strategies.
Cost burden
Within the NHS, consideration of the cost of repeated
surgeries is very important. Based on annual HES data
for 2012/2013 on admissions for sinus surgery for
CRSwNPs,25 and considering NHS reference costs of
approximately £1500 per case for each surgical admis-
sion,4 the total cost to the NHS is likely to be over £30
Figure 4 Duration of time since first sinonasal surgery for
patients with chronic rhinosinusitis with nasal polyps (surgical
time impact).
Table 3 Time to recurrence data
Diagnosis
Number of patients
with available data Mean Median
Standard
deviation Range
AFRS 22 3.7 2 3.6 12
CRSwNPs 208 10.8 7 11.9 70
CRSsNPs 82 12.9 8 13.2 46
AFRS, allergic fungal rhinosinusitis; CRSsNPs, chronic rhinosinusitis without nasal polyps; CRSwNPs, chronic rhinosinusitis with nasal
polyps.
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million per year. Although the exact proportion of revi-
sion surgeries across the NHS is not precisely known, if
50% of surgical cases are revision cases, then £15 million
is spent each year on revision sinus surgery or polypec-
tomies. As well as the ﬁnancial burden to the NHS,
there is a risk we may be subjecting patients to surgery
and its attendant complications without good evidence
of effectiveness from level 1 evidence. However, the
beneﬁt in terms of reduced healthcare costs as seen in
an American model suggests that surgery may prove
more cost-effective than continued medical therapy
alone. This recent study showed that patients with CRS
have healthcare utilisation levels at the time of surgery
that are eight times greater than baseline, but also
reach baseline levels within 13 weeks postoperatively.26
However, given the costs of surgery, good evidence on
the cost-effectiveness of repeated interventions is needed
and must be weighed up against both the direct and
indirect costs of the condition.
CONCLUSIONS
Data from the CRES show that 13 years after the
Sinonasal Audit, there is still a high burden of revision
surgery in CRS to both patients and healthcare provi-
ders. It is therefore essential, now more than ever, that
carefully designed clinical trials are undertaken that
build on the existing evidence to support surgery in
CRS and assess the effectiveness of surgery before
making such decisions. A possible trial design might
consider comparing early surgical intervention alongside
continued medical therapy versus delayed surgical
intervention on continued medical therapy to show
beneﬁt from surgery per se and also to investigate
whether or not surgery is cost-effective. Further trials are
then needed to examine the beneﬁts of extended sinus
surgery over minimal surgical intervention (eg, ENP).
This study emphasises the need for ongoing research to
improve the care of patients with CRS in order to min-
imise the need for repeated specialist care and operative
intervention.
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